Virax Biolabs Receives NASDAQ Notification Regarding Minimum Bid Price
New York, NY – July 18, 2025 – Virax Biolabs International Limited (NASDAQ: VIBX), a biotechnology company focused on the development and commercialization of diagnostic tests, announced today that it has received a notification letter from the NASDAQ Stock Market indicating a deficiency regarding the company’s compliance with NASDAQ’s minimum bid price requirement.
The notification signifies that Virax Biolabs’ common stock has not maintained a minimum closing bid price of $1.00 per share for a consecutive 30 business days, as stipulated by NASDAQ Listing Rule 5550(a)(2).
Under NASDAQ rules, listed companies are provided a compliance period of 180 calendar days to regain compliance with the minimum bid price requirement. Virax Biolabs intends to actively monitor its stock performance and explore available options to meet the minimum bid price requirement within the stipulated timeframe. The company is committed to working diligently with NASDAQ to ensure continued listing.
This development does not currently impact Virax Biolabs’ operations, its business strategy, or its ongoing commitment to advancing its diagnostic product pipeline. The company remains focused on its mission to develop and bring to market innovative diagnostic solutions that address significant unmet needs in healthcare.
Virax Biolabs will continue to keep its shareholders and the market informed of any material developments regarding its compliance status with NASDAQ listing requirements. The company’s management is dedicated to navigating this situation responsibly and in the best interest of its stakeholders.
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency’ at 2025-07-18 20:15. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.